AbbVie and Alvotech settle all US Humira litigation
Illinois court rejects dismissal of AbbVie patent case
Valeriya Zankovych / Shutterstock.com
The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.
Big pharma is no stranger to controversy, and AbbVie is perhaps one of the most lambasted.
Much criticism has been levelled against the firm for what is deemed to be an aggressive global patent strategy regarding its blockbuster drug Humira.
Humira is the brand name of the original adalimumab, an anti-inflammatory drug used to treat eleven conditions, including arthritis, psoriasis, Crohn's Disease and Spondylitis.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at email@example.com.
If you have any technical issues please email tech support.
AbbVie, Humira, Pharmaceutical Accountability Foundation, patents, biosimilars, adalimumab